Tissue Selling And Marketing Expenses vs Research Development Analysis

TRX Stock

58.50 1.50 2.50%

Tissue Regenix financial indicator trend analysis is much more than just breaking down Tissue Regenix Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tissue Regenix Group is a good investment. Please check the relationship between Tissue Regenix Selling And Marketing Expenses and its Research Development accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Selling And Marketing Expenses vs Research Development

Selling And Marketing Expenses vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tissue Regenix Group Selling And Marketing Expenses account and Research Development. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Tissue Regenix's Selling And Marketing Expenses and Research Development is 0.59. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Research Development in the same time period over historical financial statements of Tissue Regenix Group, assuming nothing else is changed. The correlation between historical values of Tissue Regenix's Selling And Marketing Expenses and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Tissue Regenix Group are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Selling And Marketing Expenses i.e., Tissue Regenix's Selling And Marketing Expenses and Research Development go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Selling And Marketing Expenses

Research Development

Most indicators from Tissue Regenix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tissue Regenix Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

As of January 7, 2025, Selling General Administrative is expected to decline to about 10.2 M. In addition to that, Tax Provision is expected to decline to about (14.5 K)

Tissue Regenix fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Other Assets	Common Stock Total Equity	Other Stockholder Equity	Total Liab	Common Stock	Common Stock Shares Outstanding	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Property Plant Equipment
Total Assets		0.93	-0.42	0.45	0.55	0.48	0.19	-0.37	0.52	0.57	0.44	-0.12	-0.56	0.45	0.26	0.47	-0.19	0.26	0.33	0.24	0.37	0.36	0.38	0.59	0.36	0.42
Total Stockholder Equity	0.93		-0.22	0.16	0.31	0.18	0.15	-0.4	0.32	0.32	0.15	-0.44	-0.26	0.24	0.55	0.22	-0.44	0.55	0.1	0.42	0.08	0.18	0.1	0.78	0.33	0.12
Other Assets	-0.42	-0.22		-0.7	-0.79	-0.79	0.52	0.03	-0.32	-0.62	-0.81	-0.45	0.77	-0.23	0.29	-0.6	-0.34	0.29	-0.11	0.14	-0.84	-0.9	-0.88	-0.06	0.3	-0.73
Common Stock Total Equity	0.45	0.16	-0.7		0.87	0.96	0.15	0.05	0.48	0.83	0.96	0.7	-0.93	0.65	-0.56	0.8	0.47	-0.56	0.63	-0.38	0.94	0.72	0.92	-0.16	0.1	0.97
Other Stockholder Equity	0.55	0.31	-0.79	0.87		0.94	-0.09	-0.08	0.65	0.94	0.9	0.63	-0.93	0.56	-0.5	0.88	0.36	-0.5	0.6	-0.08	0.87	0.76	0.88	-0.11	0.24	0.86
Total Liab	0.48	0.18	-0.79	0.96	0.94		-0.02	-0.08	0.57	0.89	0.99	0.73	-0.95	0.57	-0.58	0.88	0.51	-0.58	0.57	-0.39	0.97	0.79	0.96	-0.17	0.11	0.98
Common Stock	0.19	0.15	0.52	0.15	-0.09	-0.02		-0.08	0.16	0.07	-0.05	-0.05	-0.06	0.44	0.05	-0.01	-0.1	0.05	0.52	-0.03	-0.09	-0.43	-0.21	0.06	0.52	0.07
Common Stock Shares Outstanding	-0.37	-0.4	0.03	0.05	-0.08	-0.08	-0.08		0.0	-0.05	-0.06	0.15	0.05	-0.07	-0.19	-0.17	0.03	-0.19	0.15	0.12	-0.03	-0.06	0.03	-0.26	-0.33	-0.05
Other Current Liab	0.52	0.32	-0.32	0.48	0.65	0.57	0.16	0.0		0.81	0.5	0.37	-0.6	0.25	-0.32	0.61	0.24	-0.32	0.63	0.12	0.41	0.34	0.43	-0.08	0.43	0.48
Total Current Liabilities	0.57	0.32	-0.62	0.83	0.94	0.89	0.07	-0.05	0.81		0.85	0.62	-0.89	0.58	-0.52	0.9	0.41	-0.52	0.73	-0.1	0.77	0.64	0.8	-0.15	0.39	0.83
Property Plant And Equipment Net	0.44	0.15	-0.81	0.96	0.9	0.99	-0.05	-0.06	0.5	0.85		0.72	-0.94	0.56	-0.57	0.85	0.53	-0.57	0.51	-0.44	0.98	0.82	0.98	-0.17	0.03	0.99
Net Debt	-0.12	-0.44	-0.45	0.7	0.63	0.73	-0.05	0.15	0.37	0.62	0.72		-0.67	0.49	-0.98	0.75	0.73	-0.98	0.59	-0.52	0.71	0.5	0.71	-0.8	0.17	0.74
Retained Earnings	-0.56	-0.26	0.77	-0.93	-0.93	-0.95	-0.06	0.05	-0.6	-0.89	-0.94	-0.67		-0.65	0.53	-0.85	-0.5	0.53	-0.63	0.24	-0.91	-0.74	-0.9	0.13	-0.17	-0.93
Accounts Payable	0.45	0.24	-0.23	0.65	0.56	0.57	0.44	-0.07	0.25	0.58	0.56	0.49	-0.65		-0.44	0.65	0.28	-0.44	0.77	-0.13	0.5	0.2	0.48	-0.21	0.52	0.63
Cash	0.26	0.55	0.29	-0.56	-0.5	-0.58	0.05	-0.19	-0.32	-0.52	-0.57	-0.98	0.53	-0.44		-0.67	-0.72	1.0	-0.58	0.47	-0.55	-0.36	-0.55	0.9	-0.22	-0.59
Non Current Assets Total	0.47	0.22	-0.6	0.8	0.88	0.88	-0.01	-0.17	0.61	0.9	0.85	0.75	-0.85	0.65	-0.67		0.47	-0.67	0.67	-0.28	0.76	0.64	0.79	-0.34	0.48	0.83
Non Currrent Assets Other	-0.19	-0.44	-0.34	0.47	0.36	0.51	-0.1	0.03	0.24	0.41	0.53	0.73	-0.5	0.28	-0.72	0.47		-0.72	0.35	-0.54	0.52	0.45	0.52	-0.6	-0.03	0.53
Cash And Short Term Investments	0.26	0.55	0.29	-0.56	-0.5	-0.58	0.05	-0.19	-0.32	-0.52	-0.57	-0.98	0.53	-0.44	1.0	-0.67	-0.72		-0.58	0.47	-0.55	-0.36	-0.55	0.9	-0.22	-0.59
Net Receivables	0.33	0.1	-0.11	0.63	0.6	0.57	0.52	0.15	0.63	0.73	0.51	0.59	-0.63	0.77	-0.58	0.67	0.35	-0.58		-0.01	0.44	0.07	0.4	-0.37	0.64	0.56
Good Will	0.24	0.42	0.14	-0.38	-0.08	-0.39	-0.03	0.12	0.12	-0.1	-0.44	-0.52	0.24	-0.13	0.47	-0.28	-0.54	0.47	-0.01		-0.46	-0.25	-0.42	0.39	0.24	-0.48
Non Current Liabilities Total	0.37	0.08	-0.84	0.94	0.87	0.97	-0.09	-0.03	0.41	0.77	0.98	0.71	-0.91	0.5	-0.55	0.76	0.52	-0.55	0.44	-0.46		0.81	0.98	-0.16	-0.11	0.96
Other Current Assets	0.36	0.18	-0.9	0.72	0.76	0.79	-0.43	-0.06	0.34	0.64	0.82	0.5	-0.74	0.2	-0.36	0.64	0.45	-0.36	0.07	-0.25	0.81		0.87	-0.02	-0.22	0.75
Property Plant And Equipment Gross	0.38	0.1	-0.88	0.92	0.88	0.96	-0.21	0.03	0.43	0.8	0.98	0.71	-0.9	0.48	-0.55	0.79	0.52	-0.55	0.4	-0.42	0.98	0.87		-0.17	-0.11	0.96
Total Current Assets	0.59	0.78	-0.06	-0.16	-0.11	-0.17	0.06	-0.26	-0.08	-0.15	-0.17	-0.8	0.13	-0.21	0.9	-0.34	-0.6	0.9	-0.37	0.39	-0.16	-0.02	-0.17		-0.19	-0.2
Intangible Assets	0.36	0.33	0.3	0.1	0.24	0.11	0.52	-0.33	0.43	0.39	0.03	0.17	-0.17	0.52	-0.22	0.48	-0.03	-0.22	0.64	0.24	-0.11	-0.22	-0.11	-0.19		0.07
Property Plant Equipment	0.42	0.12	-0.73	0.97	0.86	0.98	0.07	-0.05	0.48	0.83	0.99	0.74	-0.93	0.63	-0.59	0.83	0.53	-0.59	0.56	-0.48	0.96	0.75	0.96	-0.2	0.07

Click cells to compare fundamentals

Tissue Regenix Account Relationship Matchups

Tissue Regenix fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	36.7M	34.1M	38.3M	43.2M	49.7M	30.2M
Total Stockholder Equity	28.5M	25.4M	26.0M	30.2M	34.7M	25.9M
Liabilities And Stockholders Equity	36.7M	34.1M	38.3M	43.2M	49.7M	30.3M
Other Stockholder Equity	93.5M	98.1M	138.9M	154.4M	177.5M	186.4M
Total Liab	8.9M	9.5M	13.0M	13.9M	16.0M	16.8M
Common Stock	11.7M	11.8M	13.3M	91K	104.7K	99.4K
Common Stock Shares Outstanding	44.5M	70.3M	70.3M	70.4M	81.0M	80.5M
Other Current Liab	1.4M	477.5K	4.4M	2.6M	3.0M	1.6M
Total Current Liabilities	3.3M	3.2M	5.5M	4.7M	5.4M	5.7M
Property Plant And Equipment Net	5.7M	6.7M	7.4M	9.0M	10.4M	10.9M
Net Debt	(4.2M)	175.7K	3.0M	4.7M	5.5M	5.7M
Retained Earnings	(77.7M)	(84.7M)	(96.8M)	(123.8M)	(111.4M)	(105.8M)
Accounts Payable	1.3M	2.6M	1.1M	1.2M	1.4M	921.0K
Cash	9.6M	5.7M	4.9M	4.7M	4.2M	4.0M
Non Current Assets Total	16.6M	17.8M	20.0M	24.2M	27.8M	29.2M
Non Currrent Assets Other	(8.6M)	(8.6M)	(9.6M)	(5.2M)	(6.0M)	(6.3M)
Cash And Short Term Investments	9.6M	5.7M	4.9M	4.7M	4.2M	4.0M
Net Receivables	3.5M	3.4M	4.3M	2.4M	2.7M	2.1M
Good Will	8.6M	8.6M	9.6M	11.6M	10.4M	9.1M
Non Current Liabilities Total	5.6M	6.3M	7.5M	9.2M	10.5M	11.1M
Other Current Assets	1.7M	1.2M	834.7K	4.1M	4.7M	4.9M
Property Plant And Equipment Gross	5.7M	9.1M	8.9M	14.4M	16.6M	17.4M
Total Current Assets	20.1M	16.3M	18.3M	19.1M	22.0M	20.8M
Accumulated Other Comprehensive Income	955K	197.9K	(942.7K)	(529.5K)	(608.9K)	(639.4K)
Intangible Assets	10.9M	11.1M	12.5M	3.5M	4.1M	3.9M
Property Plant Equipment	2.4M	5.7M	9.1M	8.9M	10.3M	10.8M
Net Tangible Assets	7.2M	17.7M	19.3M	17.6M	20.2M	17.7M
Inventory	7.1M	7.2M	9.0M	10.4M	11.9M	12.5M
Other Liab	670K	560K	640K	520K	468K	618.7K
Net Invested Capital	31.3M	38.8M	37.5M	36.1M	41.6M	38.4M
Net Working Capital	16.8M	17.7M	15.4M	14.4M	16.5M	15.8M
Capital Stock	9.6M	9.2M	9.2M	91K	81.9K	77.8K
Short Long Term Debt Total	5.3M	5.9M	8.0M	9.4M	10.8M	6.8M
Long Term Debt	2.8M	4.5M	5.3M	5.5M	6.4M	4.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Other Information on Investing in Tissue Stock

Balance Sheet is a snapshot of the financial position of Tissue Regenix Group at a specified time, usually calculated after every quarter, six months, or one year. Tissue Regenix Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Tissue Regenix and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Tissue currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tissue Selling And Marketing Expenses vs Research Development Analysis

Selling And Marketing Expenses vs Research Development

Selling And Marketing Expenses vs Research Development Correlation Analysis

Correlation Coefficient

Selling And Marketing Expenses

Research Development

Tissue Regenix fundamental ratios Correlations

Tissue Regenix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tissue Regenix fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Tissue Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Net	+ 0.99	Total Liab
Property Plant Equipment	+ 0.99	Property Plant And Equipment Net
Property Plant Equipment	+ 0.98	Total Liab
Non Current Liabilities Total	+ 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net

Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Retained Earnings	- 0.95	Total Liab
Retained Earnings	- 0.94	Property Plant And Equipment Net
Property Plant Equipment	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Other Stockholder Equity